Terms: = Ovarian cancer AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS AND Treatment
28 results:
1. MiRNA-mRNA integrative analysis reveals epigenetically regulated and prognostic miR-103a with a role in migration and invasion of carboplatin-resistant ovarian cancer cells that acquired mesenchymal-like phenotype.
Pernar Kovač M; Tadić V; Kralj J; Milković Periša M; Orešković S; Babić I; Banović V; Zhang W; Culig Z; Brozovic A
Biomed Pharmacother; 2023 Oct; 166():115349. PubMed ID: 37634476
[TBL] [Abstract] [Full Text] [Related]
2. Genetic analysis for mucinous ovarian carcinoma with infiltrative and expansile invasion and mucinous borderline tumor: a retrospective analysis.
Hada T; Miyamoto M; Ohtsuka Y; Suminokura J; Ito T; Kishimoto N; Nishitani S; Takada M; Imauji A; Tanabe R; Takano M
Diagn Pathol; 2023 Apr; 18(1):49. PubMed ID: 37081552
[TBL] [Abstract] [Full Text] [Related]
3. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract] [Full Text] [Related]
4. In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2.
du Manoir S; Delpech H; Orsetti B; Jacot W; Pirot N; Noel J; Colombo PE; Sardet C; Theillet C
J Pathol; 2022 Jul; 257(3):367-378. PubMed ID: 35302657
[TBL] [Abstract] [Full Text] [Related]
5. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/cbp HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of the short-term efficacy and serum markers between lobaplatin/paclitaxel- And carboplatin/paclitaxel-based adjuvant chemotherapy in patient with ovarian cancer.
Wang W; Liu M; Ding B
J Clin Pharm Ther; 2021 Feb; 46(1):166-172. PubMed ID: 33098169
[TBL] [Abstract] [Full Text] [Related]
7. 1-MT inhibits the invasion of cbp-resistant ovarian cancer cells via down-regulating IDO expression and re-activating immune cells function.
Ma H; Qin Q; Mi J; Feng Q
BMC Pharmacol Toxicol; 2020 Sep; 21(1):67. PubMed ID: 32912307
[TBL] [Abstract] [Full Text] [Related]
8. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract] [Full Text] [Related]
9. USP48 Sustains Chemoresistance and Metastasis in ovarian cancer.
Lei X; Li X; Chen H; Liu Z
Curr Cancer Drug Targets; 2020; 20(9):689-699. PubMed ID: 32359336
[TBL] [Abstract] [Full Text] [Related]
10. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Nteliopoulos G; Bazeos A; Claudiani S; Gerrard G; Curry E; Szydlo R; Alikian M; Foong HE; Nikolakopoulou Z; Loaiza S; Khorashad JS; Milojkovic D; Perrotti D; Gale RP; Foroni L; Apperley JF
Haematologica; 2019 Dec; 104(12):2400-2409. PubMed ID: 31073075
[TBL] [Abstract] [Full Text] [Related]
11. Loss of RBMS3 Confers Platinum Resistance in Epithelial ovarian cancer via Activation of miR-126-5p/β-catenin/cbp signaling.
Wu G; Cao L; Zhu J; Tan Z; Tang M; Li Z; Hu Y; Yu R; Zhang S; Song L; Li J
Clin Cancer Res; 2019 Feb; 25(3):1022-1035. PubMed ID: 30279231
[TBL] [Abstract] [Full Text] [Related]
12. β-Catenin Cooperates with CREB Binding Protein to Promote the Growth of Tumor Cells.
Yu W; Li L; Zheng F; Yang W; Zhao S; Tian C; Yin W; Chen Y; Guo W; Zou L; Deng W
Cell Physiol Biochem; 2017; 44(2):467-478. PubMed ID: 29141249
[TBL] [Abstract] [Full Text] [Related]
13. Carboplatin-Loaded, Raman-Encoded, Chitosan-Coated Silver Nanotriangles as Multimodal Traceable Nanotherapeutic Delivery Systems and pH Reporters inside Human ovarian cancer Cells.
Potara M; Nagy-Simon T; Craciun AM; Suarasan S; Licarete E; Imre-Lucaci F; Astilean S
ACS Appl Mater Interfaces; 2017 Sep; 9(38):32565-32576. PubMed ID: 28872817
[TBL] [Abstract] [Full Text] [Related]
14. A Systems Biology Comparison of ovarian cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models.
Yang MQ; Elnitski L
PLoS One; 2016; 11(10):e0163353. PubMed ID: 27788148
[TBL] [Abstract] [Full Text] [Related]
15. Valproic Acid as a Promising Co-treatment With Paclitaxel and Doxorubicin in Different ovarian Carcinoma Cell Lines.
Kwiecińska P; Taubøll E; Grzyb E; Fiedor E; Ptak A; Gregoraszczuk EL
Int J Gynecol Cancer; 2016 Nov; 26(9):1546-1556. PubMed ID: 27654264
[TBL] [Abstract] [Full Text] [Related]
16. Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.
Gao H; Yuan L; Han Y
World J Surg Oncol; 2016 Jun; 14(1):168. PubMed ID: 27341795
[TBL] [Abstract] [Full Text] [Related]
17. Upregulation of p27Kip1 by demethylation sensitizes cisplatin-resistant human ovarian cancer SKOV3 cells.
Zhao Y; Li Q; Wu X; Chen P
Mol Med Rep; 2016 Aug; 14(2):1659-66. PubMed ID: 27314502
[TBL] [Abstract] [Full Text] [Related]
18. RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells.
Mao D; Che J; Han S; Zhao H; Zhu Y; Zhu H
Mol Med Rep; 2015 Nov; 12(5):6635-41. PubMed ID: 26299671
[TBL] [Abstract] [Full Text] [Related]
19. [Effects of hyperthermia combined platinum-based drugs on ovarian cancer cell lines SKOV3].
Xie D; Yin RT; Li KM; Xiao P; Tong LX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):606-11. PubMed ID: 25286685
[TBL] [Abstract] [Full Text] [Related]
20. [Effects and mechanisms of platelet-activating factor on the invasiveness of ovarian cancer cells in vitro].
Jiang W; Wang YS; Cong Q; Li MJ; Ye B; Xu CJ
Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):931-5. PubMed ID: 22333285
[TBL] [Abstract] [Full Text] [Related]
[Next]
